Clinical Trials

60 enrolled

Sarcoma

3rd Line GIST

NCT00135005 2020-12-08

Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

59 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00301093 2020-10-28

Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

3 enrolled

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00390156 2020-07-28

Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

35 enrolled

Other solid neoplasm

Unspecified Adult Solid Tumor

NCT00047502 2018-11-07

Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia

23 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00038194 2018-10-31

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

28 enrolled

Genitourinary

Prostatic Neoplasms

NCT00401024 2018-06-28

Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma

3 enrolled

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

NCT00080665 2018-04-24

Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer

12 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00428909 2016-04-21

Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

12 enrolled

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00420043 2016-04-05

Effect of Food on Bioavailability of Modified Release Formulations of Imatinib

32 enrolled

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00422825 2016-04-05

Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib

16 enrolled

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00402766 2015-11-18

Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

Other solid neoplasmThoracic

19 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT00387933 2015-10-14

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

37 enrolled

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00052494 2015-07-23

Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

9 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT01795716 2015-05-19

Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body

21 enrolled 5 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01751919 2014-10-01

A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)

GastrointestinalMyeloidOther hematologic neoplasmSarcoma

37 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Gastrointestinal Stromal Tumors

NCT00686218 2014-08-15

Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia

Other hematologic neoplasm

9 enrolled

Leukemia, Leukemia, Myeloid, Chronic-Phase

NCT00424385 2014-07-21

Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)

17 enrolled 8 charts

Genitourinary

Prostatic Neoplasms

NCT00314873 2014-06-03

Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma

11 enrolled

Thoracic

Thymoma

NCT00183833 2014-05-22

Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors

40 enrolled

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT00004932 2014-02-21

STI571 in Treating Patients With Recurrent Leukemia

LymphoidMyeloidOther hematologic neoplasm

31 enrolled

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00258271 2013-10-16

Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Other hematologic neoplasm

18 enrolled

Blast Crisis, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT00441155 2013-05-13

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

14 enrolled

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT00253565 2013-04-08

Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors

25 enrolled

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00066326 2013-04-05

Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

NCT00354068 2013-03-28

Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma

65 enrolled

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00601510 2013-03-19

Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer

38 enrolled

Gastrointestinal

Stomach Neoplasms

NCT00613132 2013-02-20

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

78 enrolled

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00268229 2013-02-15

Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia

Other hematologic neoplasm

21 enrolled

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00611689 2013-02-04

Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors

45 enrolled

Tumor-Agnostic

Neoplasms

NCT00026169 2013-01-10

Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure

69 enrolled

Tumor-Agnostic

Neoplasms

NCT00613054 2012-12-05

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

27 enrolled

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT01270984 2012-10-31

Imatinib

GastrointestinalMyeloidOther hematologic neoplasmSarcoma

30 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Gastrointestinal Stromal Tumors

NCT00040105 2012-08-01

Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia

26 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00084513 2010-02-12

Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer

18 enrolled

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00045604 2008-07-24

Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer